General, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
J Cancer Res Clin Oncol. 2022 Apr;148(4):837-844. doi: 10.1007/s00432-022-03917-2. Epub 2022 Jan 8.
The role of CD147 as an important indicator of tumor prognosis remains controversially discussed in literature. We focused on the prognostic significance of CD147 expression in esophageal cancer patients. While some studies report that CD147 is an unfavorable prognostic factor in esophageal squamous cell carcinoma, others showed no significant correlation. However, only one study draws attention to the significance of CD147 in esophageal adenocarcinoma, which is one of the most rapidly increasing neoplasms in the western world.
To finally clarify the impact of CD147 as a prognostic factor, especially for esophageal adenocarcinomas, we analyzed CD147 expression in a tissue microarray of 359 esophageal adenocarcinomas and 254 esophageal squamous cell cancer specimens. For the immuno-histochemical analysis, we used a primary antibody specific for CD147. Staining intensity and proportion of positive tumor cells were scored (negative, weak, moderate, strong staining). These findings were compared to normal esophageal tissue and correlated to the histopathological tumor phenotype and survival data.
CD147 expression was detectable in weak intensities in benign esophageal tissue (85.78%) and expressed in predominately moderate to strong intensities in esophageal cancer (88.34%). Strong CD147 immunostaining was linked to increased infiltration depth (p = 0.015) and differentiation (p = 0.016) in esophageal squamous cell cancer but revealed no significant correlation with histopathology of adenocarcinoma. Moreover, CD147 intensity was unrelated to overall survival in this collective for both subtypes of esophageal cancer.
Thus, our data show that CD147 has no prognostic value, neither in esophageal adenocarcinoma nor squamous cell carcinoma.
CD147 作为肿瘤预后的一个重要指标，其在文献中的作用仍存在争议。我们专注于研究 CD147 表达在食管癌患者中的预后意义。虽然一些研究报告 CD147 是食管鳞状细胞癌的一个不利预后因素，但其他研究则表明两者之间没有显著相关性。然而，只有一项研究关注 CD147 在食管腺癌中的意义，而食管腺癌是西方世界增长最快的肿瘤之一。
为了最终明确 CD147 作为预后因素的意义，特别是对于食管腺癌，我们分析了 359 例食管腺癌和 254 例食管鳞状细胞癌标本的组织微阵列中 CD147 的表达。对于免疫组织化学分析，我们使用了针对 CD147 的特异性一抗。对染色强度和阳性肿瘤细胞比例进行评分（阴性、弱阳性、中度阳性、强阳性染色）。这些发现与正常食管组织进行比较，并与组织病理学肿瘤表型和生存数据相关联。
CD147 在良性食管组织中呈弱强度表达（85.78%），在食管癌中呈强至中度表达（88.34%）。强 CD147 免疫染色与浸润深度（p=0.015）和分化（p=0.016）增加相关，在食管鳞状细胞癌中，但与腺癌的组织病理学无显著相关性。此外，在这两种食管癌亚型的综合分析中，CD147 强度与总生存期无关。
因此，我们的数据表明 CD147 既没有在食管腺癌中，也没有在食管鳞状细胞癌中具有预后价值。
